Product Name: CA9 Antibody [SPM314]
Species Reactivity: Horse, Human
Tested Applications: Flow, IF
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 ug/mlWestern blot: 0.5-1 ug/mlImmunohistochemistry (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)Prediluted format: incubate for 30 min at RT (2)The optimal dilution of the CA9 antibody for each application should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: The microsomal fraction of human renal cortical tissue homogenate was used as the immunogen for this CA9 antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 292057-76-2
Product: Mcl1-IN-2
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Carbonic anhydrase 9, Carbonate dehydratase IX, Carbonic anhydrase IX, CA-IX, CAIX, Membrane antigen MN, P54/58N, Renal cell carcinoma-associated antigen G250, RCC-associated antigen G250, pMW1, CA9, G250, MN
Accession NO.:
Protein Ino:
Official Symbol: CA9
Geneid: 768
Background: Recognizes a glycoprotein of ~200kDa, identified as carbonic anhydrase IX (CAIX/CA9/gp200). Its epitope resides in the carbohydrate domain of gp200. It shows no significant cross-reactivity with other carbohydrate determinants, such as the Lewis blood group antigens, epithelial membrane antigen, HMFG, and AB blood group antigens. In normal kidney, CA9 is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowmans capsule adjoining the outgoing proximal tubule. Reportedly, CA9 is expressed by 93% of primary and 84% of metastatic renal cell carcinomas. This mAb may be useful in the investigations of carcinomas of proximal nephrogenic differentiation especially those showing tubular differentiation.
PubMed ID:http://aac.asm.org/content/42/12/3146.abstract
